Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   41189   clinical trials with a EudraCT protocol, of which   6743   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2011-006291-39
    Sponsor's Protocol Code Number:215ON201
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-10-02
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2011-006291-39
    A.3Full title of the trial
    A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis
    Estudio aleatorizado, doble ciego, en grupos paralelos, controlado con placebo para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética de BIIB033 en sujetos con el primer episodio de neuritis óptica aguda
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to compare the safety and efficacy of BIIB033 to a placebo in patients with first episode of loss of vision due to acute inflammation in the optic nerve
    Estudio para comparar la seguridad y la eficacia de BIIB033 frente a placebo en pacientes con el primer episodio de pérdida de visión debido a una inflamación aguda del nervio óptico.
    A.4.1Sponsor's protocol code number215ON201
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBiogen Idec Research Limited
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBiogen Idec Research Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBiogen Idec Research Limited
    B.5.2Functional name of contact point215ON201 Clinical Trial Team
    B.5.3 Address:
    B.5.3.1Street AddressInnovation House, 70 Norden Road
    B.5.3.2Town/ cityMaidenhead, Berkshire
    B.5.3.3Post codeSL6 4AY
    B.5.3.4CountryUnited Kingdom
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBIIB033
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNA
    D.3.9.2Current sponsor codeBIIB033
    D.3.9.3Other descriptive nameAnticuerpo monoclonal anti-LINGO-1 humano
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Acute Optic Neuritis
    Neuritis Óptica Aguda
    E.1.1.1Medical condition in easily understood language
    Acute Optic Neuritis
    Neuritis Óptica Aguda
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 15.0
    E.1.2Level PT
    E.1.2Classification code 10030942
    E.1.2Term Optic neuritis
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to evaluate the efficacy of BIIB033 in subjects with their first episode of unilateral AON.
    El objetivo principal del estudio es evaluar la eficacia de BIIB033 en sujetos con un primer episodio de Neuritis Óptica Aguda (NOA) unilateral.
    E.2.2Secondary objectives of the trial
    The secondary objective of this study in this study population is to assess the safety, tolerability, and PK of BIIB033.
    El objetivo secundario de este estudio en la población del estudio es evaluar la seguridad, tolerabilidad y farmacocinética (FC) de BIIB033.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Efficacy Endpoints for a Multifocal Visual Evoked Potential (mfVEP) Sub-Study

    Efficacy endpoint: Change in optic NCV at Week 24 for the affected eye from the baseline of unaffected fellow eye as determined by mfVEP
    Criterios de valoración de la eficacia para el subestudio del potencial visual evocado multifocal (PVE-mf)

    Criterio de valoración de eficacia: Cambio de la velocidad de conducción nerviosa (VCN) óptica en la semana 24 en el ojo afectado respecto al estado basal del ojo contralateral no afectado, determinada mediante el PVE-mf.
    E.3Principal inclusion criteria
    1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
    2. Males and females with a confirmed diagnosis (by a physician with expertise in diagnosis and treatment of diseases of the optic nerve) of a first episode of unilateral AON with an onset within 28 days prior to study dosing at Day 1/Baseline. The diagnostic criteria of AON should include at least 2 of the following: reduced visual acuity, afferent pupillary defect, color vision loss, visual field abnormality, and/or pain on eye movement. Onset of ocular pain alone cannot be used to determine the onset of AON. Subjects are allowed to enroll regardless of if there are demyelinating lesions on brain MRI.
    3. Aged 18 to 55 years old, inclusive, at the time of informed consent.
    4. Must have received treatment of AON with 1 gram IV methylprednisolone for a minimum of 3 days and a maximum of 5 days prior to randomization.
    5. All male or female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for at least 6 months after their last dose of study treatment.
    1. Capacidad de comprender el propósito y los riesgos del estudio y dar su consentimiento informado, firmado y fechado, y la autorización para usar información médica protegida (IMP), de acuerdo con la normativa nacional y local sobre la privacidad de los sujetos.
    2. Hombres y mujeres con un diagnóstico confirmado (por un médico especialista en el diagnóstico y tratamiento de enfermedades del nervio óptico) de un primer episodio de NOA unilateral, con un inicio de 28 días antes de la administración del tratamiento del estudio en el día 1/basal. Los criterios de diagnóstico de NOA deben incluir al menos 2 de los siguientes: agudeza visual reducida, defecto pupilar aferente, pérdida de la visión cromática, anomalía del campo visual y/o dolor en el movimiento del ojo. No puede usarse el inicio de dolor ocular solo para determinar el inicio de NOA. Los sujetos podrán participar en el estudio independientemente de que haya lesiones desmielinizantes en la RM cerebral o no.
    3. Los sujetos deben tener entre 18 y 55 años de edad, inclusive, en el momento del consentimiento informado.
    4. Deben haber recibido tratamiento para la NOA con 1 gramo de metilprednisolona i.v. durante un mínimo de 3 días y un máximo de 5 días antes de la aleatorización.
    5. Todos los sujetos de sexo masculino o femenino potencialmente fértiles deben usar métodos anticonceptivos eficaces durante el estudio y querer y poder continuar usándolos durante al menos 6 meses tras su última dosis del tratamiento del estudio.
    E.4Principal exclusion criteria
    1. Prior episode(s) of optic neuritis or any other previous clinical CNS demyelinating events characteristic of MS as determined by a physician with expertise in the diagnosis and treatment of MS.
    2. Subjects with an established diagnosis of MS are excluded except if newly diagnosed based on the current episode of AON and positive brain MRI results consistent with the 2010 revisions to the McDonald?s criteria. [Polman 2011].
    3. Severe refractive errors defined as myopia or hypermetropia of +/- 6 diopters sphere or worse in either eye.
    4. Loss of vision not due to AON.
    5. Previous history of, or current severe disc edema or hemorrhage.
    6. Abnormal FF-VEP in the fellow eye at Screening as determined by the central reader.
    7. Concomitant ophthalmologic disorders (e.g., diabetic retinopathy, macular degeneration, macular exudate, macular edema, glaucoma, severe astigmatism, ocular trauma, neuromyelitis optica, ischemic optic neuropathy, congenital nystagmus) or other ophthalmologic conditions that could interfere with the proposed protocol as determined by a physician with expertise in the diagnosis and treatment of ophthalmologic disorders.
    8. History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, oncologic, renal, severe allergic or anaphylactic reactions, or other major disease, as determined by the Investigator.
    9. Females who have a positive pregnancy test result, or who are pregnant, breastfeeding, or planning to conceive during the study.
    10. History of positive test result for human immunodeficiency virus (HIV).
    11. History of hepatitis C virus antibody (HCV Ab) or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]).
    12. History or evidence of drug or alcohol abuse (as defined by the Investigator) within 2 years prior to Screening.
    13. Current enrollment in any other study treatment or disease study within 3 months prior to Day 1/Baseline.
    14. Participation in previous studies with BIIB033.
    15. Inability to comply with study requirements.
    16. Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec, make the subject unsuitable for enrollment.
    1. Episodio o episodios previos de neuritis óptica o cualquier otro acontecimiento clínico previo desmielinizante del SNC característico de esclerosis múltiple (EM) según el criterio de un médico especialista en el diagnóstico y tratamiento de la EM.
    2. Los sujetos con un diagnóstico establecido de EM quedan excluidos excepto cuando sea de reciente diagnóstico, basándose en el episodio actual de NOA y los resultados positivos de RM cerebral compatibles con las revisiones de 2010 de los criterios de McDonald. [Polman 2011].
    3. Defectos refractivos graves definidos como miopía o hipermetropía de esfera de +/- 6 dioptrías o peor en cualquiera de los ojos.
    4. Pérdida de visión no debida a la NOA.
    5. Antecedentes previos o presencia actual de edema o hemorragia grave de disco.
    6. PVE-CC anormal en el otro ojo determinado por el lector central en el momento de la selección.
    7. Trastornos oftalmológicos concomitantes (p. ej., retinopatía diabética, degeneración macular, exudado macular, edema macular, glaucoma, astigmatismo severo, traumatismo ocular, neuromielitis óptica, neuropatía óptica isquémica, nistagmo congénito) u otras afecciones oftalmológicas que podrían interferir con el protocolo propuesto, según lo determine un médico con experiencia en el diagnóstico y tratamiento de trastornos oftalmológicos.
    8. Antecedentes de reacciones cardíacas, endocrinas, hematológicas, hepáticas, inmunitarias, metabólicas, urológicas, pulmonares, neurológicas, dermatológicas, psiquiátricas, oncológicas, renales, alérgicas o anafilácticas graves, clínicamente significativas, u otras enfermedades importantes, según lo determine el investigador.
    9. Mujeres que tengan un resultado positivo en la prueba de embarazo, o que estén embarazadas, en período de lactancia o con intención de concebir durante el estudio.
    10. Antecedentes de resultado positivo en el análisis del virus de la inmunodeficiencia humana (VIH).
    11. Antecedentes de anticuerpos contra el virus de la hepatitis C (VHC Ab) o del virus de la hepatitis B (definido como resultado positivo del antígeno de superficie de la hepatitis B [HBsAg] o de anticuerpos contra el antígeno nuclear de la hepatitis B [HBcAb]).
    12. Antecedentes o evidencia de abuso de drogas o alcohol (según la definición del investigador) en el plazo de 2 años antes de la selección.
    13. Participación en cualquier otro tratamiento del estudio o estudio de una enfermedad en el plazo de 3 meses antes del día 1/basal.
    14. Participación en estudios previos con BIIB033.
    15. Incapacidad para cumplir con los requisitos del estudio.
    16. Otra razón no especificada que, en opinión del investigador o de Biogen Idec, provoque que el sujeto no sea adecuado para su inclusión.
    E.5 End points
    E.5.1Primary end point(s)
    Primary Efficacy Endpoint: Change in optic nerve conduction velocity (NCV) at Week 24 for the affected eye from the baseline of unaffected fellow eye as determined by full-field visual evoked potential (FF-VEP).
    Criterio principal de valoración de la eficacia: Cambio de la velocidad de conducción del nervio (VCN) óptico en la semana 24 en el ojo afectado respecto al estado basal del ojo otro ojo no afectado, determinada según el potencial visual evocado de campo completo (PVE-CC).
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 24
    Semana 24
    E.5.2Secondary end point(s)
    Secondary Efficacy Endpoint:
    -Change in thickness of the RNFL at Week 24 for the affected eye from the baseline of unaffected fellow eye as determined by spectral-domain optical coherence tomography (SD-OCT).

    -Change in thicknesses of the retinal ganglion cell layer/inner plexiform retinal layer (RGCL/IPL) at Week 24 for the affected eye from the baseline of unaffected fellow eye as determined by segmentation of SD-OCT.

    -Change in LCLA at Week 24 from baseline as determined by 1.25% and 2.5% low-contrast Sloan letter charts.

    Safety Endpoints:
    The following safety parameters will be used to address the safety and tolerability portion of the secondary objective:
    -Adverse events (AEs) and serious adverse events (SAEs)
    -Clinical laboratory results and vital sign measurements
    -Physical examination findings
    -Brain MRI results
    -12-lead electrocardiogram (ECG) readings
    -AON signs and symptoms

    PK Endpoint:
    The PK portion of the secondary objective will be addressed by a population PK assessment
    Criterio secundario de valoración de la eficacia:
    - Cambio en el grosor de la capa de fibras nerviosas de la retina (CFNR) en la semana 24 en el ojo afectado respecto al estado basal del otro ojo no afectado, medido por la tomografía de coherencia óptica de dominio espectral (SD OCT).
    - Cambio en los grosores de la capa de células ganglionares de la retina/capa plexiforme interna de la retina (CCGR/CPI) en la semana 24 en el ojo afectado respecto al estado basal del otro ojo no afectado, determinado según la segmentación de la SD-OCT.
    - Cambio en la agudeza visual con letras de bajo contraste (ALBC) en la semana 24 respecto al estado basal, determinada mediante el optotipo de letras de Sloan de bajo contraste de 1,25 % y 2,5 %.

    Criterios de valoración de la seguridad:
    Se utilizarán los siguientes parámetros de seguridad para abordar la parte de seguridad y tolerabilidad del objetivo secundario:
    - Acontecimientos adversos (AA) y acontecimientos adversos graves (AAG)
    - Resultados de laboratorio clínico y mediciones de las constantes vitales
    - Hallazgos de la exploración física
    - Resultados de resonancias magnéticas (RM) cerebrales
    - Lecturas de electrocardiogramas (ECG) de 12 derivaciones
    - Signos y síntomas de la NOA

    Criterio de valoración FC:
    La parte FC del objetivo secundario se abordará a través de una evaluación FC de la población
    E.5.2.1Timepoint(s) of evaluation of this end point
    Efficacy endpoints: Week 24
    Safety/PK endpoints: Throughout the course of the study
    Criterios de valoración de la eficacia: Semana 24
    Criterios de valoración de la seguridad/FC: A lo largo del curso del estudio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA31
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Czech Republic
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last subject, last visit
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 80
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 62
    F.4.2.2In the whole clinical trial 80
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After participation in the trial, if applicable, patients may be treated with the current standard therapy. For subjects with AON who have multiple sclerosis or are considered to be at increased risk of developing multiple sclerosis, follow up will be done by a local neurologist. The study investigator will refer the patient to a neurologist if they don?t already have one
    Después de la participación en el ensayo, si aplica, los pacientes pueden ser tratados con el tratamiento estándar actual. Para los sujetos con NOA que tienen esclerosis múltiple o que se considere tienen un alto riesgo de desarrollar esclerosis múltiple, el seguimiento lo realizará un neurólogo local. El investigador del estudio remitirá el paciente a un neurólogo si todavía no tiene uno.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-11-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-11-08
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice